Colorectal cancer vaccine - Oryx

Drug Profile

Colorectal cancer vaccine - Oryx

Alternative Names: Frame shift peptide colorectal cancer vaccine; FSP colorectal cancer vaccine; MicOryx; Vaccine MSI - Oryx

Latest Information Update: 07 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oryx GmbH & Co
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colorectal cancer

Most Recent Events

  • 07 Jan 2016 Colorectal cancer vaccine is available for licensing before Jan 2016.
  • 22 Sep 2015 Phase I/II development is ongoing in Germany
  • 04 Mar 2015 Oryx GmbH completes a phase I/II trial in Colorectal cancer in Germany (NCT01461148,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top